Therapeutic options for immune-mediated thrombocytopenia

Journal of Veterinary Emergency and Critical Care

Volumn 22, Issue 1, 2012, Pages 59-72

  Nakamura, Reid K ^a   Tompkins, Emily ^b   Bianco, Domenico ^c  

^a The case was managed at VCA Advanced Veterinary Care Center   (United States)

^b Mid Atlantic Equine Medical Center   (United States)

^c VCA Shoreline Veterinary Referral Emergency Center   (United States)

Author keywords

Autoimmune disorders; Immune thrombocytopenic purpura; Immune mediated thrombocytopenia; Immunoglobulin therapy; Treatment

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB; THROMBOPOIETIN RECEPTOR; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; DRUG POTENTIATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; VINCRISTINE;

EID: 84864321561     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2011.00705.x     Document Type: Review

References (177)

1. Lewis DC, Meyers KM. Canine idiopathic thrombocytopenic purpura. J Vet Intern Med 1996; 10:207-218.
2. Lewis DC, Meyers KM, Callan MB, et al. Detection of platelet-bound and serum platelet-bindable antibodies in the diagnosis of canine ITP. J Am Vet Med Assoc 1995; 206:47-52.
3. Putsche JC, Kohn B. Primary immune-mediated thrombocytopenia in 30 dogs. J Am Anim Hosp Assoc 2008; 44:250-257.
4. Lewis DC, Meyers KM. Studies of platelet-bound and serum platelet-bindable immunoglobulins in dogs with idiopathic thrombocytopenic purpura. Exp Hematol 1996; 24:696-701.
5. Helfand SC, Couto CG, Madewell BR. Immune-mediated thrombocytopenia associated with solid tumors. J Am Anim Hosp Assoc 1985; 21:787-794.
6. Kohn B, Galke B, Beelitz P, et al. Clinical features of canine granulocytic anaplasmosis in 18 naturally infected dogs. J Vet Intern Med 2008; 22:1289-1295.
7. Grindem CB, Breitschwerdt EB, Perkins PC, et al. Platelet associated immunoglobulin (antiplatelet antibody) in canine Rocky Mountain spotted fever and ehrlichiosis. J Am Anim Hosp Assoc 1999; 35:56-61.
8. Waner T, Harrus S, Weiss DJ, et al. Demonstration of serum antiplatelet antibodies in experimental acute canine ehrlichiosis. Vet Immunol Immunopathol 1995; 48:177-182.
9. Kristensen AT, Weiss DJ, Klausner JS, et al. Detection of antiplatelet antibodies with a platelet immunofluorescence assay. J Vet Intern Med 1994; 8:36-39.
10. Kohn B, Engelbrecht R, Leibold W, et al. Clinical findings, diagnostics, and treatment results in primary and secondary immune-mediated thrombocytopenia in the dog. Kleintierpraxis 2000; 45:893-907.
11. Wilkerson MJ, Shuman W, Swist S, et al. Platelet size, platelet surface-associated IgG, and reticulated platelets in dogs with immune-mediated thrombocytopenia. Vet Clin Pathol 2001; 30:141-149.
12. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113(11):2386-2393.
13. Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122(6):966-974.
14. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4(11):2377-2383.
15. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98(5):436-442.
16. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-186.
17. Kuhne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observation study. Lancet 2001; 358(9299):2122-2125.
18. Nuenert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117(16):4190-4207.
19. Friedman D, Nettl F, Schrieber AD. Effect of estradiol and steroid analogue on the clearance of immunoglobulin G-coated erythrocytes. J Clin Invest 1985; 75:162-167.
20. Ruiz P, Gomez F, King M, et al. In vivo glucocorticoid modulation of guinea pig splenic macrophage Fc gamma receptors. J Clin Invest 1991; 88:149-157.
21. Gernsheimer T, Stratto J, Ballem PJ, et al. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 1989; 320:974-980.
22. Fujisawa K, Tani P, Piro L, et al. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. Blood 1993; 81:2872-2877.
23. Kitchens CS. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. J Clin Invest 1977; 60:1129-1134.
24. Kitchens CS, Weiss L. Ultrastructural changes of endothelium associated with thrombocytopenia. Blood 1975; 46(4):567-578.
25. Blajchman MA, Senyl FA, Hirsh J, et al. Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest 1979; 63:1026-1035.
26. Bellucci S, Charpak Y, Chastang C, et al. Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of randomized clinical trial in 160 children, 223 adults. Blood 1988; 71:1165-1169.
27. Mazzucconi MG, Francesconi M, Fidani P, et al. Treatment of idiopathic thrombocytopenic purpura (ITP): results of a multicentric protocol. Haematologica 1985; 70:329-336.
28. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial. Lancet 2002; 359:23-29.
29. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330(22):1560-1564.
30. Stasi R, Brunetti M, Pagano A, et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000; 26(6):582-586.
31. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109(4):1401-1407.
32. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349:831-836.
33. Alpdogan O, Budak-Alpdogan T, Ratip S, et al. Efficacy of high dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br J Haematol 1998; 103:1061-1063.
34. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
35. Kimberly RP, Salmon JE, Bussel JB, et al. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984; 132:745-750.
36. Saleh M, Court W, Huster W, et al. Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets. Br J Haematol 1988; 68:47-51.
37. Winiarski J, Kreuger A, Ejderhamn J, et al. High dose intravenous IgG reduces platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura. Scan J Haematol 1983; 31:342-348.
38. Delfraissy JF, Tschernia G, Laurian Y, et al. Suppressor cell function after intravenous gamma globulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985; 60:315-322.
39. Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987; 52:206-211.
40. Caroll RR, Noyes WD, Kitchens CS. High-dose intravenous immunoglobulin therapy in patients with immune thrombocytopenic purpura. J Am Med Assoc 1983; 249:1748-1750.
41. Godeau B, Lesage S, Divin M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993; 82:1415-1421.
42. Bussel J. Intravenous immune serum globulin in immune thrombocytopenia: clinical results and biochemical evaluation. Vox Sang 1985; 49(suppl 1):44-50
43. Godeau B, Caulier MT, Decuypere L, et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999; 107:716-719.
44. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344:703-707.
45. Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997; 130:281-283.
46. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients for the treatment for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78(6 suppl 2):35-40.
47. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8(110);1788-1794.
48. Katz U, Schoenfeld Y. Intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005; 1:802-808.
49. Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol 1998; 35(1, suppl 1):14-22.
50. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89:2689-2700.
51. Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity and mechanism of effect. Blood 1991; 77:1884-1893.
52. Carr JM, Kruskall MS, Kaye JA, et al. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80(6):1051-1054.
53. Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol 2008; 83(2):122-125.
54. Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113:1564-1573.
55. Slichter SJ, Kaufman RM, Assman SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600-613.
56. Ferrara F, Copia C, Annanziata M, et al. Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura. Ann Hematol 1999; 78:521-523.
57. Chamouni P, Lenain P, Buchonnet G, et al. Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine. Transfus Sci 2000; 23:101-106.
58. Boruchov DM, Guruangan S, Driscol MC, et al. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007; 110(10):3526-2531.
59. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47(2-3):63-83.
60. Heyman B. Regulation of antibody responses via antibodies, complement and Fc receptors. Ann Rev Immunol 2000; 18:70-737.
61. Quiquandon I, Fenaux P, Caulier MT, et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990; 74(2):223-228.
62. Yenson PR, Forrest D, Schmiegelow K, et al. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Am J Hematol 2008; 83(1):80-83.
63. Kelsey PR, Schofield KP, Geary CA. Refractory idiopathic thrombocytopenic purpura treated with cyclosporine. Br J Haematol 1985; 60:179-203.
64. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10:118-123.
65. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporine A in refractory idiopathic thrombocytopenic purpura. Blood 2002; 99(4):1482-1485.
66. Kappers-Klunne MC, Vant Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic pupura refractory to corticosteroids or splenectomy. Br J Haematol 2001; 114(1):121-125.
67. Verlin M, Laros RK, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamide. Am J Hematol 1976; 1(1):87-104.
68. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85(2):351-358.
69. Krause JR. Chronic idiopathic thrombocytopenic purpura (ITP) development of acute lymphocytic leukemia subsequent to treatment with cyclophosphamide. Med Pediatr Oncol 1982; 10(1):61-65.
70. Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndromes. Br J Haematol 1991; 77:502-508.
71. Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia, unmaintained remission and age-dependent response in women. Ann Intern Med 1989; 111:723-729.
72. McVerry BA, Avger M, Bellingham AJ. The use of danazol in the management of chronic immune thrombocytopenic purpura. Br J Hematol 1985; 61:145-148.
73. Maloisel F, Andres E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004; 116(9):590-594.
74. Ahn YS, Horstman LL. Idiopathic thrombocytopenic purpura: pathophysiology and management. Int J Hematol 2002; 76(suppl 2):123-131.
75. Danovitch G. Mycophenolate mofetil: a decade of clinical experience. Transplantation 2005; 80(S2):S272-S273.
76. Appel G, Radhakrishnan J, Ginzer E. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005; 80(S2):S265-S271.
77. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165:2374-2381.
78. Provan D, Moss AJ, Newland AC, et al. Efficacy of mycophenolate mofetil as single agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006; 81(1):19-25.
79. Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory autoimmune cytopenias: a single center preliminary study. Eur J Haematol 2005; 75(1):60-64.
80. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98:952-957.
81. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002; 69:95-100.
82. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146(1):25-33
83. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2008; 93(6):930-933.
84. Fianchi L, Rossi M, Murri R, et al. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 2007; 86(3):225-226.
85. Lissoni P, Mandala M, Rossini F, et al. Growth factors: thrombopoietic property of the pineal hormone melatonin. Hematology 1999; 4(4):335-343.
86. Todisco M, Rossi N. Melatonin for refractory idiopathic thrombocytopenic purpura: a report of 3 cases. Am J Ther 2002; 9(6):524-526.
87. Todisco M, Casaccia P, Rossi N. Severe bleeding symptoms in refractory idiopathic thrombocytopenic purpura: a case of successfully treated with melatonin. Am J Ther 2003; 10(2):135-136.
88. Todisco M. Melatonin makes splenectomy unnecessary in two patients with idiopathic thrombocytopenic purpura refractory to corticosteroids. J Pineal Res 2007; 43(2):214.
89. Vancine-Califani SMC, De Paula EV, Ozelo MC, et al. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic pupura. Platelets 2008; 19(7):489-495.
90. Byrd SR, Gelber RH. Effect of dapsone on haemoglobin concentration in patients with leprosy. Lepr Rev 1991; 62:171-178.
91. Durand JM, Lefevre P, Hovette P, et al. Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol 1991; 78:459-460.
92. Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352:878.
93. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113:1231-1240.
94. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995; 74(1):521-525.
95. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein for chronic ITP. N Engl J Med 2006; 355(16):1672-1681.
96. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109(11):4607-4617.
97. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357(22):2237-2247.
98. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889-1899.
99. Schwartz J, Leber MD, Gillis S, et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003; 72(2):94-98.
100. Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104(9):2623-2634.
101. Johansson E, Engervall P, Landgren O, et al. Response to splenectomy is durable after a certain point in adult patients with chronic immune thrombocytopenic purpura. Eur J Haematol 2006; 77(1):61-66.
102. Masseau A, Guitton C, Bretonniere C, et al. Plasma exchanges as treatment of severe acute immune thrombocytopenic purpura. Rev Med Interne 2005; 26(10):824-826.
103. O'Marra SK, Delaforcade AM, Shaw SP. Treatment and predictors of outcome in dogs with immune-mediated thrombocytopenia. J Am Vet Med Assoc 2011; 238:346-352.
104. Wilkins RJ, Hurvitz AL, Dodds WJ. Immunologically mediated thrombocytopenia in the dog. J Am Vet Med Assoc 1973; 163:277-282.
105. Williams DA, Maggio-Price L. Canine idiopathic thrombocytopenic purpura: clinical observation and long-term follow-up in 54 cases. J Am Vet Med Assoc 1984; 185:660-663.
106. Jans HE, Armstrong PJ, Price GS. Therapy of immune-mediated thrombocytopenia. A retrospective study of 15 dogs. J Vet Intern Med 1990; 4:4-7.
107. Jackson ML, Kruth SA. Immune-mediated hemolytic anemia and thrombocytopenia in the dog: a retrospective study of 55 cases diagnosed from 1969 through 1983 at the Western College of Veterinary Medicine. Can Vet J 1985; 26:245-250.
108. Rozanski EA, Callan MB, Hughes D, et al. Comparison of platelet recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. J Am Vet Med Assoc 2002; 220:477-481.
109. Callan MB, Appleman EH, Sachais BS. Canine platelet transfusions. J Vet Emerg Crit Care 2009; 19(5):401-415.
110. Guillaumin J, Jandrey KE, Norris JW, et al. Analysis of a commercial dimethyl-sulfoxide-stabilized frozen canine platelet concentrate by turbidimetric aggregometry. J Vet Emerg Crit Care 2010; 20(6):571-577.
111. Appleman EH, Sachais BS, Patel R, et al. Cryopreservation of canine platelets. J Vet Intern Med 2009; 23(1):138-145.
112. Greene CE, Scoggin J, Thomas JE, et al. Vincristine in the treatment of thrombocytopenia in five dogs. J Am Vet Med Assoc 1982; 180:140-143.
113. Feldman BF, Handagama P, Lubberink AA. Splenectomy as adjunctive therapy for immune-mediated thrombocytopenia and hemolytic anemia in the dog. J Am Vet Med Assoc 1985; 187:617-619.
114. Huang HP, Yang HL, Liang SL, et al. Iatrogenic hyperadrenocorticism in 28 dogs. J Am Anim Hosp Assoc 1999; 35(3):200-207.
115. Toombs JP, Collins LG, Graves GM, et al. Colonic perforation in steroid-treated dogs. J Am Vet Med Assoc 1986; 188:145-150.
116. Effects of prednisone alone and prednisone with ultralow-dose aspirin on gastro-duodenal mucosa in healthy dogs. J Vet Intern Med 2009; 23(3):482-487.
117. Rose L, Bedard C, Dunn M. Effect of prednisone administration of thromboelastography parameters in healthy beagles. J Vet Intern Med 2008; 22:738-739 (abstract).
118. Cohn LA, DeClue LE, Reinero CR. Endocrine and immunologic effects of inhaled fluticasone propionate in healthy dogs. J Vet Intern Med 2008; 22:37-43.
119. Swinney GR, Foster SF, Church DB, et al. Myotonia associated with hyperadrenocorticism in two dogs. Aust Vet J 1998; 76(11):722-724.
120. Reagan WJ, Scott-Moncrieff JC, Christian J, et al. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Am J Vet Res 1998; 59:1568-1574.
121. Bianco D, Armstrong PJ, Washabau RJ. A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs. J Vet Intern Med 2009; 23:1071-1078.
122. Bianco D, Armstrong PJ, Washabau RJ. Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. J Vet Intern Med 2007; 21:694-699.
123. Bianco D, Hardy RM. Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog. J Am Anim Hosp Assoc 2009; 45:147-150.
124. Tsuchiya R, Akutsu Y, Ikegami A, et al. Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs. J Vet Intern Med 2009; 23:1164-1169.
125. O'Brien MA, Rudolff E, Kirby R. Intravenous equine immunoglobulin G for use in the treatment of immune-mediated hemolytic anemia in the dog. J Vet Emerg Crit Care 2007; 17(3s1):S7 (abstract).
126. Golden DL, Langston VC. The uses of vincristine and vinblastine in dogs and cats. J Am Vet Med Assoc 1988; 93:1114-1117.
127. Mackin AJ, Allen DG, Johnstone IB. Effects of vincristine and prednisone on platelet numbers and function in clinically normal dogs. Am J Vet Res 1995; 56:100-108.
128. Grau-Bassas ER, Kociba GH, Couto CG. Vincristine impairs platelet aggregation in dogs with lymphoma. J Vet Intern Med 2000; 14:81-85.
129. Gregory CR. Immunosuppressive agents, In: Kirk RW, Gonagura JD. eds. Kirk's Current Veterinary Therapy XIII. Philadelphia, PA: Saunders; 2000, pp. 509-513.
130. Harkin KR, Phillips D, Wilkerson M. Evaluation of azathioprine on lesion severity and lymphocyte blastogenesis in dogs with perianal fistulas. J Am Anim Hosp Assoc 2007; 43(1):21-26.
131. Whitley NT, Day MJ. Immunomodulatory drugs and their application to the management of canine immune-mediated diseases. J Sm Anim Pract 2011; 52:70-85.
132. Kidd LB, Salavaggione OE, Szumlanski CL, et al. Thiopurine methyltranferase activity in red blood cells of dogs. J Vet Intern Med 2004; 18:214-218.
133. Salavaggione OE, Kidd L, Prondzinski JL, et al. Canine red blood cell thiopurine S-methyltransferase; companion animal pharmacogenesis. Pharmacogenetics 2002; 12:713-724.
134. Beale KM. Azathioprine for treatment of immune-mediated disease of dogs and cats. J Am Anim Hosp Assoc 1988; 192:1316-1318.
135. Houston DM, Taylor JA. Acute pancreatitis and bone marrow suppression in a dog given azathioprine. Can Vet J 1991; 32(8):496-497.
136. Finkardt NE, Kruth SA. Azathioprine-induced bone marrow toxicity in four dogs. Can Vet J 1996; 37:612-613.
137. Robson D. Review of the pharmacokinetics, interactions and adverse reaction of cyclosporine in people, dogs, and cats. Vet Rec 2003; 152:739-748.
138. Cook AK, Bertoy EH, Gregory CR, et al. Effect of oral cyclosporine (CS) in dogs with refractory immune-mediated anemia (IMA) or thrombocytopenia (ITP). J Vet Intern Med 1994; 8:170 (abstract).
139. Rosenkrantz WS, Griffin CE, Barr RJ. Clinical evaluation of cyclosporine in animal models with cutaneous immune-mediated disease and epitheliotropic lymphoma. J Am Anim Hosp Assoc 1988; 25:337-384.
140. Blackwood L, German AJ, Stell AJ, et al. Multicentric lymphoma in a dog after cyclosporine therapy. J Small Anim Pract 2004; 45:259-262.
141. Callan MB, Preziosi D, Mauldin E. Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinoma in situ in a dog following chronic treatment with prednisone and cyclosporine. Vet Derm 2005; 16:338-345.
142. Schmiedt CW, Grimes JA, Holzman G, et al. Incidence and risk factors for development of malignant neoplasia after feline renal transplantation and cyclosporine-based immunosuppression. Vet Comp Oncol 2009; 7(1):45-53.
143. Ogilvie GC, Felsburg PJ, Harris CW. Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol 1988; 18:119-127.
144. Mason M, Duval D, Shofer FS, et al. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med 2003; 17:206-212.
145. Marin MP, Samson RJ, Jackson ER. Hemorrhagic cystitis in a dog. Can Vet J 1996; 37(4):240.
146. Ruther U, Nunnensiek C, Schmoff HJ. Secondary neoplasias following chemotherapy, radiotherapy and immunosuppression. Contrib Oncol 2000; 55:36-61.
147. Roseler BJ, Mason KV. Use of danazol and corticosteroids for the treatment of immune-mediated thrombocytopenia in a dog. Aust Vet Pract 1994; 24:126-130.
148. Bloom JC, Meunier LD, Thiem PA, et al. Use of danazol for treatment of corticosteroid-resistant immune-mediated thrombocytopenia in a dog. J Am Vet Med Assoc 1989; 194(1):76-78.
149. Al-Ghazlat S. Immunosuppressive therapy for canine IMHA. Comp Cont Educ Pract Vet 2009; 31:33-41.
150. Welder AA, Robertson JW, Melchert RB. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. J Pharmacol Toxicol Methods 1995; 33:187-195.
151. Gregory CR, Silva HT, Patz JD, et al. Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocytes stimulation in humans, rhesus macaques, cats, dogs, and rats. Transplant Proc 1998; 30(4):1047-1048.
152. Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory disease of dogs that are unresponsive to conventional therapy. Transplant Proc 1998; 30(8):4143-4148.
153. Singer LM, Cohn LA, Reinero CR, et al. Pharmacokinetics of leflunomide in healthy dogs. J Vet Intern Med 2010; 24:708.
154. Yuki M, Sugimoto N, Otsuka H, et al. Recovery of a dog from aplastic anemia after treatment with mycophenolate mofetil. Aust Vet J 2007; 85:495-497.
155. Abelson AL, Shelton GD, Whelan MF, et al. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs. J Vet Emerg Crit Care 2009; 19(4):369-374.
156. Dewey CW, Boothe DM, Wilkie WS. Pharmacokinetics of single dose oral and intravenous mycophenolate mofetil administration in normal dogs. J Vet Intern Med 2001; 15:304 (abstract).
157. Platz KP, Sollinger HW, Hullett DA, et al. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991; 51:27-31.
158. Matus RE, Schrader LA, Leifer CE, et al. Plasmapheresis as adjuvant therapy for autoimmune hemolytic anemia. J Am Vet Med Assoc 1985; 186:691-693.
159. Matus RE, Gordon BR, Leifer CE, et al. Plasmapheresis in five dogs with systemic immune-mediated disease. J Am Vet Med Assoc 1985; 187:595-599.
160. Crump KL, Seshadri R. Use of therapeutic plasmapheresis in a case of canine immune-mediated hemolytic anemia. J Vet Emerg Crit Care 2009; 19(4):375-380.
161. Orcutt ES, Lee JA, Bianco D. Immune-mediated hemolytic anemia and severe thrombocytopenia in dogs: 12 cases (2001-2008). J Vet Emerg Crit Care 2010; 20(3):338-345.
162. Goggs R, Boag AK, Chan DL. Concurrent immune-mediated haemolytic anaemia and severe thrombocytopenia in 21 dogs. Vet Rec 2008; 163(11):323-327.
163. Joshi BC, Raplee RG, Powell AL, et al. Autoimmune thrombocytopenia in a cat. J Am Anim Hosp Assoc 1979; 15:585-588.
164. Jordan HL, Grindem CB, Breitschwerdt EB. Thrombocytopenia in cats: a retrospective study of 41 cats. J Vet Intern Med 1993; 7:261-265.
165. Tasker S, Mackin AJ, Day MJ. Primary immune-medated thrombocytopenia in a cat. J Sm Anim Prac 1999; 40:127-131.
166. Garon CL, Scott MA, Selting KA, et al. Idiopathic thrombocytopenic purpura in a cat. J Am Anim Hosp Assoc 1999; 35:464-470.
167. Bianco D, Armstrong PJ, Washabau RJ. Presumed primary immune-mediated thrombocytopenia in four cats. J Fed Med Surg 2008; 10:495-500.
168. Wondratschek C, Weingart C, Kohn B. Primary immune-mediated thrombocytopenia in cats. J Am Anim Hosp Assoc 2010; 46:12-19.
169. Beale KM, Altman D, Clemmons RR, et al. systemic toxicosis associated with azathioprine administration in domestic cats. Am J Vet Res 1992; 53:1236-1240.
170. Zini E, Hauser B, Meli ML, et al. Immune-mediated erythroid and megakaryocytic aplasia in a cat. J Am Vet Med Assoc 2007; 230:1024-1027.
171. Lien YH, Huang HP, Chang PH. Iatrogenic hyperadrenocorticism in 12 cats. J Am Anim Hosp Assoc 2006; 42(6):414-423.
172. Chun R, Garrett LD, Vail DM. Cancer chemotherapy, In: Withrow SJ, Vail DM. eds. Small Animal Clinical Oncology. 4th edn. St. Louis, MO: Saunders; 2007, pp. 163-192.
173. Hahn K, Fletcher C, Legendre A. Marked neutropenia in five tuimor-bearing cats one week following single-agent vincristine sulfate chemotherapy. Vet Clin Pathol 1996; 25:121-123.
174. Morrison WB. Chemotherapy, In: Morrison WB. ed. Cancer in Dogs and Cats: Medical and Surgical Management. 2nd edn. Jackson, WY: Teton New Media; 2002, pp. 350-351.
175. Barrs VR, Martin P, Beatty JA. Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporine therapy. Aust Vet J 2006; 84:30-35.
176. Kadar E, Sykes JE, Kass PH, et al. Evaluation of the prevalence of infections in cats after renal transplantation: 169 cases (1987-2003). J Am Vet Assoc 2005; 227(6):948-953.
177. Bernsteen L, Gregory CR, Kyles AE, et al. Renal transplantation in cats. Clin Tech Small Anim Pract 2000; 15(1):40-45.